Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
Sunday, August 2, 2009 - 15:42
in Health & Medicine
SAN FRANCISCO (August 1, 2009) -- Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.